In summary, our results suggest that combining radiotherapy and an HMGB1 inhibitor, or targeting TLR2, may be considered a new therapeutic strategy to avoid pancreatic-carcinoma relapse and distant metastasis. Here, HMGB1 is linked to exocrine pancreatic carcinoma.